Black adler syrup
SUBSTANCE: black adler syrup having laxative action, characterised by the fact that it is produced by preparing black adler tea by boiling the raw material with purified water; the tea is further mixed with refined sugar; the mixture is heated until the sugar is dissolved completely and brought to boil twice with skimming as often as it may be required; the prepared syrup is filtered through gauze in the certain environment.
EFFECT: syrup is high in anthracene derivatives and possesses the pronounced laxative action.
2 dwg, 1 ex
The invention relates to chemical-pharmaceutical industry, in particular to the production of a pharmaceutical agent that has a laxative effect, the syrup obtained by water extraction from bark of buckthorn (Frangula alnus Mill.) (1).
In official medicine as a source of laxatives widely used buckthorn bark brittle due to the high content in it anthracenedione. The Russian Federation has registered the following medications derived from bark of buckthorn: Buckthorn extract tablets, coated 0.2 g" and "Buckthorn syrup" (2).
"Buckthorn syrup" was selected as a prototype of the invention. It is known that liquid dosage forms are more bioavailable because the active ingredients are already in dissolved form. However, in the production of 1 liter prototype used an aqueous extract of 830 g buckthorn bark, raising questions regarding the completeness of the extraction of active compounds from medicinal plants. Small release of active compounds leads to inefficient use of raw materials and inefficient economic costs (2).
Thus, the aim of the invention is to provide a composition and a more rational technology of syrup.
The technical result of the proposed method �is obtaining syrup of buckthorn bark brittle with use of more efficient technologies, saving of raw materials three times.
This object is achieved in that in the beginning a decoction from the bark of buckthorn in the ratio 1:3 by boiling for 15 min and the use of extract obtained in the manufacture of syrup of the following composition:
|A decoction of buckthorn bark brittle (1:3)||36,0|
|Refined sugar||Of 64.0|
To study the UV spectra of the obtained syrups in alkali-ammonia medium and the quantitative determination of anthracenedione, an accurately weighed sample of syrup (2.0 g) was placed in a volumetric flask with a capacity of 25 ml, was diluted to the mark and stirred (original solution). 2 ml of the resulting solution was placed in a volumetric flask with a capacity of 25 ml and was adjusted to the mark alkali-ammonia solution (test solution). The test solution was heated for 15 min in a boiling water bath.
After cooling, removed the electronic spectrum of the test solution in the range 190-700 nm. As of the reference solution used used purified water.
The content of the sum of anthracenedione (X) in terms of glucofrangulin frangulin A percentage calculated as follows:
where D is the optical density of the test solution;
D0optic n�otnesti solution RDF mangulina A;
m is the mass of a sample of syrup, g;
m0- mass RDF mangulina And,
When no standard sample mangulina And it is advisable to use theoretical value of the specific rate of absorption - 180 (3,4):
where D is the optical density of the test solution;
180 - specific absorption coefficientalkali-ammonia solution RDF mangulina And at 524 nm.
For the quantitative determination of anthracenedione investigated in the initial samples buckthorn bark used a previously developed methodology (extractant - 40% ethanol, ratio of raw material:extractant 1:50, the extraction time of 90 min) (3, 4).
The inventive method is implemented by the following example.
Example 1. 12.0 g buckthorn bark raw material filled in 62 ml (taking into account the coefficient of water absorption) of purified water at room temperature, was heated on a hotplate to boil, boil the contents of the flask for 15 min, cooled for 15 min, filtered and adjusted, if necessary, obtained to the required volume ratio of raw material:a decoction of 1:3.
Water extraction from bark of buckthorn (decoction) was used instead of purified water to obtain a sugar syrups pharmacopoeial method. For this, 36 g of decoction was mixed with 64 g of refined sugar and heated the mixture until the sugar is dissolved, bring to Ki�message twice each time removing the resulting foam. The syrup was filtered through cheesecloth in hot form and brought to the initial mass of purified water.
The content of the sum of anthracenedione in the finished product in terms of glucofrangulin frangulin And was 0.37±0,02% (yield from raw materials 47,7±0,4%).
The purpose of the comparison received syrup of buckthorn brittle following compositions: syrups derived similarly to the inventive method, but using broth 1:1 (prototype), 1:6, 1:3 when heated in a water bath. The resulting syrups were less sum of anthracenedione (in syrup of decoction of 1:6 content was 0.15%±0,01%; flavor broth 1:3 (heating in a water bath) - 0,30±0,02%), except for the syrup, corresponding to the prototype, in which the content did not differ statistically significantly from the proposed composition and amounted 0,39±0,02%. However, all the syrups were inferior to the proposed composition of output the amount of anthracenedione of raw material: syrup decoction 1:6 output is 38.6±0,5%, in syrup of decoction of 1:3 (heating in a water bath) of 31.6±0,4%; in syrup-prototype output was the lowest of the considered examples and was 18.1±0,5% (Fig. 1).
Comparative characteristics of the considered method and the method prototype is shown in Fig. 1. On the basis of obtained data we can conclude that the proposed method is characterized by more wysockiego existing connections and not inferior to the prototype method for the quantitative content of anthracenedione. Technology is also more rational, so as the same amount of syrup is obtained from the quantity of raw materials, three times smaller in comparison with the prototype.
Also conducted a comparative evaluation of the laxative effect of syrup of buckthorn, obtained the claimed method, and syrup of buckthorn (prototype). For this white mongrel rats-albinos of both sexes weighing 250 g, fed last 6 hours before the experiment (standard diet of the vivarium), were placed separately in cages, with clean filter paper. Experimental and control groups were composed of 10 animals each. The study drugs were administered to animals in the experimental groups intraperitoneally in amounts equivalent to dosages of 5 mg/kg, 10 mg/kg, 25 mg/kg 50 mg/kg and 100 mg/kg in recalculation on anthracenedione (Fig. 2). In the case of a large volume of administered drugs (over 8 ml) broth, including for the preparation of syrups, evaporated. 18 hours after administration of test samples were calculated with a total number of faeces from each animal of all analyzed groups. The percentage increase of the faeces and the proportion of wet faeces from their total number was considered a laxative effect.
Determined that in the case of syrup of buckthorn, obtained the claimed method, the maximum laxative effect is achieved at a dose of 50 mg/kg, whereas in the case of the proto�IPA comparative laxative effect is achieved at a dose of 100 mg/kg (Fig. 2). Consequently, syrup of buckthorn, obtained the claimed method, in 2 times is more active some syrup of buckthorn, obtained by the method prototype.
Sources of information
1. Kurkin V. A. Fundamentals of herbal medicine: a textbook for students of pharmaceutical universities. - Samara: LLC "Etching", GOU VPO "Samara state medical University of Roszdrav", 2009. - 963 S.
2. The state register of drugs // the Ministry of health of the Russian Federation. URL: http://grls.rosminzdrav.ru/default.aspx (reference date: 02.02.2014 g ).
3. Kurkin V. A., Sigareva A. A. Determination of anthracenedione in the buckthorn bark brittle // pharmacy. - 2010. - Vol. 58. - No. 8. - S. 9-12.
4. Kurkin V. A., Sigareva A. A. Phytochemical investigation of buckthorn bark brittle // Medical almanac. - 2012. - №1 (20). - P. 218-220.
5. Chueshov V. I., Chernov, M. Y., Khokhlova L. M., etc. Industrial technology of drugs: a Textbook for students of higher educational institutions. In 2 vols 2 - Kharkiv: NUPH MTC. Book, 1999. - 704 S.
Syrup of buckthorn bark brittle, has a laxative effect, characterized in that it is obtained by preparation of decoction of buckthorn bark brittle at a ratio of raw material:a decoction of 1:3 by boiling raw material with the purified water for 15 min, then 36 g of decoction was mixed with 64 g of refined sugar, heat the mixture until the sugar is dissolved, bring to the boil twice, each time removing obesulus� foam, the resulting syrup was filtered through cheesecloth.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to compounds of formula , wherein A means a six-merous aryl radical or a five-merous heteroaryl radical which contains one heteroatom specified in oxygen and sulphur; one or more hydrogen atoms in the above aryl or heteroaryl radicals can be substituted by substituting groups R1 which are independently specified in a group consisting of: F, Cl, Br, I, (C1-C10)-alkyl-, (C1-C10)-alkoxy-, -NR13R14; B means a radical with mono- or condensed bicyclic rings specified in a group consisting of: six-ten-merous aryl radicals, five-ten-merous heteroaryl radicals and nine-fourteen-merous cycloheteroalkylaryl radicals, wherein cycloheteroalkyl links can be saturated or partially unsaturated, while the heterocyclic groups can contain one or more heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, one or more hydrogen atoms in the radical groups B can be substituted by substituting groups R5 (as specified in the patent claim), L means a covalent bond, X means the group -O-, R2 is absent or means one or more substitutes specified in F and (C1-C4)-alkyl radical; R3 and R4 independently mean (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C4-C20)-cycloalkylalkyl, (C2-C19)-cycloheteroalkyl, (C3-C19)-cycloheteroalkylalkyl, (C6-C10)-aryl, (C7-C20)-arylalkyl, (C1-C9)-heteroaryl, (C2-C19)-heteroarylalkyl radicals, or R3 and R4 together with nitrogen attached whereto can form a four-ten-merous saturated, unsaturated or partially unsaturated heterocyclic compound which can additionally contain one or more heteroatoms among -O-, -S(O)n-, =N- and -NR8-; other radicals are such as specified in the patient claim. Also, the invention refers to using the compound of formula I for preparing a drug.
EFFECT: compounds of formula (I) as Na+/H+ metabolism inhibitors NHE3.
22 cl, 27 dwg, 1 tbl, 756 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents a composition containing polyethylene glycol 30 to 150 g, an ascorbic acid ingredient 3 to 20 g specified in ascorbic acid, ascorbic acid salt, or a mixture thereof, alkali or alkali earth sulphate, and at least one electrolyte specified in sodium chloride, potassium chloride, and sodium hydrocarbonate in one litre of an aqueous solution; it additionally contains flavouring agents and is effective in the colon cleansing for preparing for an endoscopy, particularly a colonoscopy. The invention contains a unit dose for preparing the colon cleansing solution, the colon cleansing solution, the method for preparing and using the same, and the kit for preparing and using the colon cleansing solution.
EFFECT: composition is safer than the standard colon cleansing compositions of sodium phosphate, and thereby may be used for the patients exposed to an elevated risk of using the composition of sodium phosphate, and is more tolerable than the standard compositions of PEG (polyethylene glycol) leading to a better compliance with the regimen and providing the effective use by outpatients.
48 cl, 6 ex, 29 tbl
SUBSTANCE: invention relates to granules as a laxative, containing particles of magnesium oxide of formula Mg2+ 1-xZn2+ x)O (1) with the average diameter of secondary particles 0.1-25 mcm and apparent specific volume 3-20 ml/g. In formula (1) X represents number from 0 to 0.02, content of magnesium oxide particles constitutes from 80 to 95 wt %. Granules also include mannitol and carmellose and have the average particle diameter 0.2-0.4 mm and bulk density 0.4-0.7 g/ml. Content of particles in granules, which have particle diameter from less than 500 mcm to not less than 355 mcm, constitutes from 30 to 45 wt %, content of particles, which have particle diameter from less than 355 mcm to not less than 180 mcm constitutes from 40 to 50 wt %, content of particles, which have particle diameter from less than 180 mcm to not less than 150 mcm, constitutes from 10 to 28 wt %.
EFFECT: granules of magnesium oxide possess good solubility, attractive taste and outlook and do not leave sense of roughness in the oral cavity.
4 cl, 7 tbl, 2 dwg, 7 ex
SUBSTANCE: invention refers to medicine, namely gastroenterology, and may be used for treating the patients with the first stage cholelithiasis. That is ensured by administering the preparation Mucofalc 1 sachet 3 times a day for 22-24 weeks.
EFFECT: method enables extending the range of drug preparations having litholytic action in the first stage cholelithiasis with no side effects.
2 tbl, 2 ex
SUBSTANCE: invention refers to medicine, particularly to methods for patient's preparation for diagnostic and therapeutic medical interventions requiring a clean intestine. To prepare the intestine for the medical interventions with using Fortrans (Macrogol), a required quantity of sachets per one intake is calculated according to the table, particularly if a body weight is less than 50 kg and the age is under 50 years old - 1 sachet, the age is between 51 to 70 years old - 1-2 sachets, over 71 years old - 1 sachet, a body weight of 51-70 kg and the age under 50 years old - 1-2 sachets, the age of 51-70 years old - 2-3 sachets, over 71 years old - 2 sachets; a body weight more than 71 kg and the age under 50 years old - 2 sachets, 51-70 years old - 3 sachets, over 71 years old - 2 sachets. Besides, the presence of constipations requires +1 sachet; 1 sachet of Fortrans is dissolved in 1 litre of water.
EFFECT: using the method enables extending the indications, taking into account and coping the contraindications, reducing and eliminating the side effects, preparing in the more sparing regimen with underlying minimal emotional load.
3 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to an antacid and laxative tablet that contains magnesium oxide particles of the diameter of 0.5 to10 mcm as a main ingredient in the amount of 85 to 96 wt %. The claimed tablet contains crystalline cellulose 2-8 wt % as a binding agent, sodium croscarmellose 0.8-2.5 wt % as a disintegrating agent 1, insoluble polyvinyl pyrrolidone 1-3.5 wt % as a disintegrating agent II and a lubricant 0.5-2 wt %. The invention also refers to a method for preparing the above tablet that involves the mixing of the magnesium oxide particles, crystalline cellulose and the lubricant, and the dry granulation of the prepared mixture to produce the magnesium oxide granules, the mixing of crystalline cellulose, insoluble polyvinyl pyrrolidone and the lubricant with the magnesium oxide granules, and the tableting of the produced granules. The invention also refers to using the claimed tablet for antacid and laxative applications.
EFFECT: invention provides preparing the tablet that preserves the long-storage properties of fast disintegration, possess high friability and forms fewer impact cracks and splits.
15 cl, 15 tbl, 1 dwg, 30 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns a pharmaceutical combination for treating a condition which indicates for using an opioid, containing oxycodone and a prostaglandin compound of formula
a based pharmaceutical composition, a kit for sales and use of the above pharmaceutical combination for preparing the therapeutic agent for treating the condition which indicates for using the opioid.
EFFECT: combination shows higher efficacy.
21 cl, 1 tbl, 1 ex
SUBSTANCE: what is presented is the use of an ileal bile acid transporter (IBAT) inhibitor representing some benzothiazepine derivatives for preparing a drug for the use in treating and/or preventing constipation in a warm-blooded animal and human. The invention consists in ileal bile acid transportation wherein the bile acids are used as endogenous relaxants.
EFFECT: it is shown that the IBAT administration increases a fecal matter amount after the animals kept the low-fibre and high-protein diet or in a model of constipation either caused by morphine hydrochloride, or following typhlectomy.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutical compositions for preparing infusion solutions of antibacterial and antimycotic preparations, and to methods for preparing them. The declared pharmaceutical compositions are presented in the form of powder, contain sodium chloride and dextrose and particles of colloidal silicone dioxide among which a portion of particles of 5 mcm and less makes less than 35%, in certain weight proportions. A method for preparing said pharmaceutical compositions consists in the fact that sodium chloride in the form of powder and dextrose in the form of powder are mixed with powdered colloidal silicone dioxide in certain proportions; the prepared mixture is mechanically treated by impact abrasion to increase a weight portion of fine particles of silicone dioxide of 5 mcm or less to min. 35%.
EFFECT: group of inventions provides the intensified therapeutic effectiveness of parenteral forms of the antibacterial and antimycotic preparations.
4 cl, 4 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to method of manufacturing compositions, containing potassium bicarbonate and sodium picosulfate, which includes stage of application by spraying sodium picosulfate solution on potassium bicarbonate and drying of said salts with formation of granules, containing sodium picosulfate layer on potassium bicarbonate core. Invention also relates to composition, suitable for obtaining composition, which possesses laxative action, which contains granules, including sodium picosulfate layer, applied on potassium bicarbonate core. Invention also relates to composition, possessing laxative action, and to method of its obtaining, which contains granules of homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, and possibly sodium saccharin and/or orange flavouring agent, with granules containing sodium picosulfate, applied on potassium bicarbonate core.
EFFECT: invention is aimed at obtaining composition, which can be used for emptying of bowels before X-ray examination, endoscopy or surgery, which is homogeneous and possesses improved characteristics.
34 cl, 2 dwg, 3 ex
SUBSTANCE: invention refers to medicine and cosmetology, namely to deep cosmetic products, and can be used for normalising physiological functions of skin and eliminating endogenous or exogenous defects. The invention represents a cosmetic product for fast skin repair containing superoxide dismutase, dexpanthenol, succinic acid, trolox and L-arginine. The product is applied on the skin for 20 minutes with using a material holding the agent and feeding it to the skin over the period of exposure.
EFFECT: cosmetic product enables extending the range of products for improving the skin state, reducing the risk of lower controllability of the effect, and a probability of allergic and inflammatory reactions.
3 cl, 10 ex
SUBSTANCE: using a polyphenolic complex produced by extracting milled ash berry in 40% ethanol, condensing the alcohol-water extract, adding 95% ethanol, centrifuging the residue, filtering and condensing the supernatant in the certain environment, as an agent possessing anti-inflammatory action.
EFFECT: polyphenolic complex possesses pronounced anti-inflammatory action.
1 dwg, 9 tbl, 7 ex
SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.
EFFECT: declared group of inventions is highly effective in treating bovine mastitis.
3 cl, 5 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to pharmaceutical composition, containing compound of formula or for prevention or treatment of diseases, associated with oxidative stress, selected from group, consisting of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke episodes), MERRF syndrome (myoclonic epilepsy with ragged red fibres) or Kearns-Sayre syndrome, arrhythmia, cardioplegia or myocardium infarction. in formula (1) na stands for 1 or 2, Aa represents 5-membered heteroaryl or heterocycle, each of which has 2 heteroatoms, selected from N, O and S, Rla represents R5a-Xa-Ba-X′a-, Ba represents direct bond, Xa and X′a independently on each other represent direct bond or -OC(O)-, R5a represents hydrogen or 6-9-membered monocyclic or condensed cyclic heterocycle or heteroaryl, each of which has from 1 to 3 heteroatoms, selected from N, O and S, and is optionally substituted with oxo or C1-C6-alkyl, R2a represents -(CR8aR9a)pa-Ya-R7a , pa stands for number from 0 or 1, Ya represents direct bond or -O-, R7a represents hydrogen or phenyl, R3a, R8a, R9a, R10a represent hydrogen, R4a represents -(CH2)pa-Da-R10a-, Da represents C5-cycloalkyl or 6-membered heterocycle, which has 1 heteroatom, selected from N, S and O. Radical values for formula (2) are give in invention formula.
EFFECT: obtaining compositions for prevention or treatment of diseases, associated with oxidative stress.
19 dwg, 5 tbl, 3 ex
SUBSTANCE: opening of a carious cavity, ablation of overhanging enamel edges on the entire circumference, necrectomy and drug treatment with a 0.06% chlorhexidine solution are performed. The preparation "Lemifaren" is applied on walls and bottom of the carious cavity in a uniform 1 mm thick layer, which is left for 1 day under temporary filling. After the removal of the preparation irradiation in a pulse mode with the power of 5 W and frequency of 2000-3000 Hz is carried out for 5 min with the application of the laser apparatus ALST-01. After that, the cavity is restored with an account of functional and aesthetic parameters of the particular tooth.
EFFECT: effective treatment of deep caries prevents caries recurrences and pulp inflammation.
SUBSTANCE: method involves administering an anthelminthic agent in the period of stationary process stage; the anthelminthic treatment is preceded by administering chophytol 200 mg 3 times a day before meals for 14 days; the anthelminthic treatment involves administering Osinol food supplement 2 tablets 3 times a day during meals for 14 days; thereafter, chophytol is taken in a dose of 200 mg 3 times a day before meals for 14 days; 7 days later, the repeated course of the anthelminthic treatment with Osinol food supplement 2 tablets 3 times a day during meals is prescribed to be administered for 14 days; the entire therapeutic course involves washing the face with the Setaphyldermocontrol foaming facial cleanser 2 times a day followed by applying an SPF30 product on the face once after the morning wash.
EFFECT: reducing the number of complications and the high efficacy of the anthelminthic treatment.
SUBSTANCE: invention relates to cosmetic industry and provides a composition for depositing on keratin surfaces, which contains composition particles in the form of fused agglomerates having a part containing at least one dye and a part containing at least one transparent and translucent thermoplastic material, where the composition particles contain, based on the weight of all of the powdered composition material, about 10 to 90 parts of the dye part and about 90 to 10 parts of the transparent and translucent thermoplastic material part, and a method of producing the powdered composition material.
EFFECT: invention enables to obtain cosmetic compositions which will have an improved outer appearance on the skin and fewer SKU.
23 cl, 10 tbl, 11 ex
SUBSTANCE: group of inventions relates to medicine and is intended for oral cavity care. Compositions contain: a) guanidine-based active substance, b) film-forming polymer, c) hydrophobic modifier of viscosity in quantity, sufficient for provision of composition for oral cavity care with time particle sedimentation more than 20 minutes, and d) oil carrier. Guanidine-based active substance preferably represents L-arginine. Film-forming polymer preferably represented GANTREZ. Hydrophobic modifier of viscosity preferably represents thickened mineral oil. Oil carrier preferably represents natural oil. Composition is enclosed in gelatine capsule. Method of teeth cleaning includes application on teeth of composition for oral cavity care in such a way that composition for oral cavity care cleans teeth. Device for oral cavity care, which contains: handle, fastened on handle head, where head has external surface and a row of teeth-cleaning elements, projecting outwards on external surface, and gelatine capsule, which contains composition for oral cavity care, located on head.
EFFECT: group of inventions makes it possible to increase teeth cleaning efficiency.
14 cl, 2 ex, 1 tbl
SUBSTANCE: invention relates to the encapsulation of active ingredients and to processing textile materials. Claimed are: a method of processing textile materials, containing microcapsules of active ingredients, fibres and/or textile materials, obtained from the said method, and their cosmetic or pharmaceutical application and/or their application as a repellent.
EFFECT: claimed invention makes it possible to increase the active ingredient stability for an acceptable number of washings.
16 cl, 6 dwg
SUBSTANCE: invention relates to application of composition, which contains Polygonum aviculare grass 20-25 wt %, cowberry leaves 13-17 wt %, Viburnum sargentii koehne fruits 5-9 wt %, fruits of dog-rose of different of Far-East species 20-25 wt %, Schisandra chinensis seeds 13-17 wt %, Fragaria orientalis leaves 5-9 wt % and corn stigmas 5-9 wt %, as means with oil protective activity in treatment of glomerulonephritis.
EFFECT: invention provides positive influence on basic indices of glomerulonephritis: promotes recovery of diuresis, reduction of proteinuria, reduction of azotemia, cryoglobulinemia and level of circulating immune complexes.
FIELD: medicine, oncology, amino acids.
SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.
EFFECT: valuable medicinal antitumor properties of preparation.
8 cl, 4 tbl, 2 dwg, 4 ex